bluebird bio, Inc. (NASDAQ:BLUE) saw an uptick in trading volume on Tuesday after SunTrust Banks raised their price target on the stock to $223.00. SunTrust Banks currently has a buy rating on the stock. 1,358,454 shares were traded during trading, an increase of 61% from the previous session’s volume of 843,380 shares.The stock last traded at $192.70 and had previously closed at $201.80.

BLUE has been the subject of several other reports. Morgan Stanley raised shares of bluebird bio from an “underweight” rating to an “equal weight” rating in a research note on Friday, November 3rd. Evercore ISI raised shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price objective for the company in a research note on Monday, October 16th. Maxim Group set a $170.00 price objective on shares of bluebird bio and gave the stock a “buy” rating in a research note on Friday, November 17th. Goldman Sachs Group reissued a “buy” rating and issued a $186.00 price objective on shares of bluebird bio in a research note on Friday, October 6th. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $158.00 price objective (up from $134.00) on shares of bluebird bio in a research note on Tuesday, September 5th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the stock. bluebird bio currently has a consensus rating of “Buy” and an average price target of $155.10.

In other news, insider Philip D. Gregory sold 2,250 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $172.54, for a total value of $388,215.00. Following the completion of the sale, the insider now owns 28,734 shares in the company, valued at approximately $4,957,764.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Davidson sold 4,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $131.31, for a total transaction of $525,240.00. The disclosure for this sale can be found here. Insiders sold a total of 99,550 shares of company stock valued at $14,413,376 in the last 90 days. Company insiders own 3.90% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of bluebird bio by 9.6% in the 2nd quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock worth $705,301,000 after acquiring an additional 587,236 shares during the last quarter. Capital Research Global Investors lifted its holdings in bluebird bio by 9.9% during the 2nd quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after buying an additional 493,072 shares in the last quarter. Baillie Gifford & Co. lifted its holdings in bluebird bio by 3.8% during the 2nd quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock valued at $567,339,000 after buying an additional 196,025 shares in the last quarter. Vanguard Group Inc. lifted its holdings in bluebird bio by 10.7% during the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after buying an additional 343,856 shares in the last quarter. Finally, BlackRock Inc. lifted its holdings in bluebird bio by 4.3% during the 2nd quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock valued at $348,801,000 after buying an additional 138,141 shares in the last quarter.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The company had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. During the same quarter in the previous year, the business earned ($2.07) EPS. The company’s quarterly revenue was up 397.4% compared to the same quarter last year. research analysts anticipate that bluebird bio, Inc. will post -6.68 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “bluebird bio (BLUE) Sees Strong Trading Volume on Analyst Upgrade” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/bluebird-bio-blue-sees-strong-trading-volume-on-analyst-upgrade/1760325.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with Analyst Ratings Network's FREE daily email newsletter.